Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05390905
Other study ID # HSK21542-303
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 8, 2022
Est. completion date March 28, 2023

Study information

Verified date April 2023
Source Haisco Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, double-blind, placebo/active-controlled study. About 387 subjects undergoing elective abdominal operation under general anesthesia are planned to be enrolled and randomized into the HSK21542 group (129 subjects), tramadol group (129 subjects), and placebo group (129 subjects).


Recruitment information / eligibility

Status Completed
Enrollment 387
Est. completion date March 28, 2023
Est. primary completion date December 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. 18 = age = 70 years old, male or female; 2. The American Society of Anesthesiologists (ASA) Class I-II; 3. 18 kg/m2 = BMI (body mass index) = 40 kg/m2; 4. Subjects undergoing elective abdominal operation under general anesthesia (including laparoscopic surgery); 5. Subjects with an NRS score = 4 at rest within 4 h after the surgery (when the last stitch of suture is completed) determined by investigators; 6. Subjects who agree to participate in this trial and voluntarily sign the informed consent form. Exclusion Criteria: Previous and concomitant diseases 1. Subjects with a history or evidence of any of the following diseases before screening: 1. History of cardiovascular diseases: uncontrolled hypertension (systolic blood pressure [SBP] = 170 mmHg and/or diastolic blood pressure [DBP] = 105 mmHg without treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment), aneurysm, serious arrhythmia, heart failure, Adams-stokes syndrome, the New York Heart Association (NYHA) Class = III, serious superior vena cava syndrome, serious pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding subjects with pacemakers); 2. History of respiratory system disorders: serious chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, serious airway stenosis, throat mass, history of tracheoesophageal fistula or airway tear, serious respiratory infection within 2 weeks before screening; 3. History of neurologic and psychiatric disorders: craniocerebral injury, convulsions, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of psychotropic drugs, and history of cognitive dysfunction; history of depression, anxiety, and epilepsy, etc.; 4. History of acute poisoning with alcohol, hypnotics, analgesics, or other central nervous system acting drugs; 5. History of any major surgery within 3 months before screening, which may affect postoperative pain assessment as judged by investigators. Past and concomitant medications 2. Known allergies or contraindications to opiates and other drugs that might be used in the clinical trial such as anesthetics (propofol/sevoflurane), muscle relaxants (cisatracurium), antiemetics (tropisetron); 3. Receipt of any one of the following medications or treatments at screening(with the exception of drugs specified in the protocol): 1. Use of opioid and non-opioid (such as paracetamol, aspirin [daily dose > 100 mg], indometacin, diclofenac, parecoxib sodium, and other non-steroidal anti-inflammatory drugs) analgesics with the interval between the last administration and randomization shorter than 5 half-lives of the drug or the duration of response (whichever is longer); 2. Consecutive use of opioid analgesics for any reason of more than 10 days within 3 months before screening; 3. Use of drugs with unknown half-lives that affect the analgesic effects within 14 days before randomization, or use of drugs that affect the analgesic effects with the interval between the last administration and randomization within 5 half-lives or duration of drug effect (calculated at maximum) (as per the packaging insert); such drugs include but are not limited to: sedative hypnotics (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (anesthetic ether, nitrous oxide, sodium thiopental, ketamine, etomidate, etc.), glucocorticoids (dexamethasone hydrochloride, methylprednisolone, etc.), antiepileptics (carbamazepine, sodium valproate, etc.), anxiolytics (chlordiazepoxide, diazepam, etc.), antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines or Chinese patent medicines that may affect efficacy evaluation as judged by investigators; 4. Use of diuretics and compound drugs containing diuretics with the interval between the last administration and randomization shorter than 5 half-lives of the drug or the duration of response (whichever is longer). Laboratory and other tests 4. The laboratory test parameters measured at screening reach one of the following criteria: 1. White blood cell count < 3.0 x 109/L; 2. Platelet count < 80 x 109/L; 3. Hemoglobin < 70 g/L; 4. Prolongation of prothrombin time (PT) exceeding the upper limit of normal (ULN) for 3 seconds; 5. Prolongation of activated partial thromboplastin time (APTT) exceeding the ULN for 10 seconds; 6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2 x ULN; 7. Total bilirubin > 1.5 x ULN; 8. Blood creatinine > 1.5 x ULN; 9. Fasting blood glucose = 11.1 mmol/L; 5. Positive for hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody at screening; Other circumstances 6. History of medication abuse, drug abuse, or alcohol abuse within 3 months before screening (alcohol abuse is defined as average daily alcohol drinking > 2 units of alcohol [1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150 mL of wine]); 7. History of blood donation or blood loss of = 400 mL within 3 months before screening; 8. Participation in other clinical trials within 3 months before screening (defined as the receipt of investigational product or placebo); 9. Pregnant or breastfeeding females; females of child-bearing potential or males who are reluctant to use contraception during the trial; or subjects who are planning pregnancy within 3 months after the completion of the trial (including male subjects); 10. Subjects judged by investigators to have any other factors unsuitable for participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HSK21542 Injection
1µg/kg/dose
Tramadol hydrochloride
50mg/dose
placebo
placebo

Locations

Country Name City State
China Union Hospital, Tongji Medical College, Huazhong U Wuhan

Sponsors (1)

Lead Sponsor Collaborator
Haisco Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the placebo group Time-weighted SPID at rest within 0-24 h after the first administration in the HSK21542 group and the placebo group From administration until 24 hours after administration
Primary Sum of Pain Intensity Differences (SPID) in tramadol group and the placebo group Time-weighted SPID at rest within 0-24 h after the first administration in the tramadol group and the placebo group From administration until 24 hours after administration
Primary Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the tramadol group Time-weighted SPID at rest within 0-24 h after the first administration in the HSK21542 group and the tramadol group From administration until 24 hours after administration
Secondary Use of remedial analgesics within 0-12 h Cumulative used amount of remedial analgesics within 0-12 h after the first administration, percentage of subjects not using remedial analgesics, and start time of remedial analgesic use From administration until 12 hours after administration
Secondary Use of remedial analgesics within 0-24 h Cumulative used amount of remedial analgesics within 0-24 h after the first administration, percentage of subjects not using remedial analgesics, and start time of remedial analgesic use From administration until 24 hours after administration
Secondary Sum of Pain Intensity Differences (SPID) in each group Time-weighted SPID at rest within 0-12 h after the first administration From administration until 12 hours after administration
Secondary Pain intensity difference (PID) The PID at rest at each scoring time point after the first administration From administration until 24 hours after administration
Secondary Numerical rating scale(NRS)in each group The NRS score at each scoring time point after the first administration From administration until 24 hours after administration
Secondary Numerical rating scale(NRS)at 0-12 h The ratio of subjects with NRS score = 3 for resting pain at 0-12 h after the first administration From administration until 12 hours after administration
Secondary Numerical rating scale(NRS)at 0-24 h The ratio of subjects with NRS score = 3 for resting pain at 0-24 h after the first administration From administration until 24 hours after administration
Secondary Duration of analgesia after the first administration duration of NRS score = 3 within 24 h after the first postoperative administration or the sum of the duration of NRS score = 3 with fluctuations in pain within 24 h From administration until 24 hours after administration
Secondary Satisfaction scores on postoperative analgesia Subject satisfaction score and investigator satisfaction score on postoperative analgesia at 24 h after the first administration From administration until 24 hours after administration
See also
  Status Clinical Trial Phase
Completed NCT05023850 - Comparing Thoracolumbar Interfascial Plane Block With Erector Spinae Plane Block N/A
Completed NCT06205199 - Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty N/A
Not yet recruiting NCT06062550 - Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery Phase 4
Completed NCT03239314 - Analgesic Effect of Adductor Canal Block With and Without Dexamethasone for Knee Arthroscopy N/A
Completed NCT05317572 - Comparison of Three Different Doses of Intrathecal Morphine for Analgesia After Cesarean Section N/A
Recruiting NCT06157359 - Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection N/A
Completed NCT03258255 - Analgesic Efficiency of Pudendal Nerve Block Versus Penil Block for Circumsion in Children N/A
Recruiting NCT06430112 - Liposomal Bupivacaine vs Ropivacaine for TAPBs Phase 3
Recruiting NCT06078241 - Postoperative Analgesia in Patients Undergoing Percutaneous Nephrolithotomy N/A
Completed NCT04579302 - Serratus Anterior Block and Erector Spinae Block in Postoperative Analgesia N/A
Completed NCT04111848 - Magnesium and Ketamine in Postoperative Analgesia Phase 4
Completed NCT03341234 - Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection N/A
Recruiting NCT03540537 - A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy N/A
Terminated NCT02150161 - Opioid vs. Opioid-free Anesthesia for Hip Arthroscopy Phase 3
Not yet recruiting NCT01589354 - Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery N/A
Completed NCT05855798 - Ketamine and Magnesium in Erector Spinae Plane Block Phase 4
Not yet recruiting NCT04845711 - Ultrasound Guided Erector Spinae Plane Block Versus Quadratus Lumborum Block in Laparoscopic Cholecystectomy N/A
Completed NCT03131375 - Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia Phase 2/Phase 3
Completed NCT03885427 - Analgo-Sedative Effects Of Oral, Or Nebulized Ketamine In Pre-schoolers Undergoing Elective Surgery. Early Phase 1
Completed NCT04738357 - A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia Phase 3